Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

PURPOSE: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2021
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189949/
https://ncbi.nlm.nih.gov/pubmed/33748921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06145-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados